News

HDA UK Media And Political Bulletin – 7 March 2018

Media and Political Bulletin

7 March 2018

Media Summary

PM says UK should try to remain a member of the EMA after Brexit

The Pharmaceutical Journal, 6 March 2018

 

The Pharmaceutical Journal reports on the Prime Minister’s Brexit speech on 2 March. In Theresa May’s speech on 2 March 2018, billed as her vision for the future economic partnership between the UK and the European Union, she spoke of her commitment to seeking for the UK to remain part of “critical” EU agencies, including the EMA.

“Membership of the European Medicines Agency would mean investment in new innovative medicines continuing in the UK, and it would mean these medicines getting to patients faster as firms prioritise larger markets when they start the lengthy process of seeking authorisations,” she said.

“But it would also be good for the EU because the UK regulator assesses more new medicines than any other member state. And the EU would continue to access the expertise of the UK’s world-leading universities.”

May said the government would “explore with the EU, the terms on which the UK could remain part of EU agencies” including the EMA.

And she said: “We would, of course, accept that this would mean abiding by the rules of those agencies and making an appropriate financial contribution.”

 

Parliamentary Coverage

 

There is no parliamentary coverage today.

 

Full Coverage

PM says UK should try to remain a member of the EMA after Brexit

The Pharmaceutical Journal, 6 March 2018

The UK should seek to remain a member of the European Medicines Agency (EMA), the Prime Minster has said.

In her speech on 2 March 2018, billed as her vision for the future economic partnership between the UK and the European Union (EU), Theresa May spoke of her commitment to seeking for the UK to remain part of “critical” EU agencies, including the EMA.

“Membership of the European Medicines Agency would mean investment in new innovative medicines continuing in the UK, and it would mean these medicines getting to patients faster as firms prioritise larger markets when they start the lengthy process of seeking authorisations,” she said.

“But it would also be good for the EU because the UK regulator assesses more new medicines than any other member state. And the EU would continue to access the expertise of the UK’s world-leading universities.”

May said the government would “explore with the EU, the terms on which the UK could remain part of EU agencies” including the EMA.

And she said: “We would, of course, accept that this would mean abiding by the rules of those agencies and making an appropriate financial contribution.”

Government ministers had previously stated that they wanted a post-Brexit UK to “work closely” with the EMA.

Niall Dickson, co-chair of the Brexit Health Alliance, which represents many UK healthcare organisations, including the NHS Confederation, the Academy of Medical Royal Colleges, and the Association of the British Pharmaceutical Industry, said it was “good to hear the desire to remain part of the European Medicines Agency, to abide by its rules, and make appropriate financial commitments”.

“That is the best way to make sure patients have quick access to the drugs and treatments they need,” he said.

British Medical Association treasurer, Andrew Dearden commented that he was “pleased” to see that the government wanted to explore associate membership of the EMA.

“We want to see the government work closely with the EMA through a formal agreement to continue to support and participate in their assessments for medicines approvals,” he said.

Steve Bates, chief executive of the BioIndustry Association, which represents the UK bioscience industry, remarked: “It’s good to see the PM articulating the practical dynamics of our industry of the future, when she said in her speech that membership of the European Medicines Agency would mean investment in new innovative medicines continuing in the UK, and it would mean these medicines getting to patients faster as firms prioritise larger markets when they start the lengthy process of seeking authorisations.”

HDA UK Media And Political Bulletin – 7 March 2018

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?